بسم الله الرحمن الرحيم

MONA MAGHRABY

شبكة المعلومات الجامعية

التوثيق الالكتروني والميكروفيلم

MONA MAGHRABY

شبكة المعلومات الجامعية

التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات

يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار

MONA MAGHRABY

Evaluation of Some long non coding RNAs in Chronic Lymphocytic Leukemia

"A Thesis submitted for degree of Science as a partial fulfillment for requirements of Master of science"

Summited by

Marwa Adel Abou- Elwafa

B.Sc. in Biochemistry and nutrition, 2011
(Girls College (Science) – Ain Shams University)

Under supervision of

Prof. Dr. Magdy Mahmoud Mohamed
Professor of Biochemistry
Faculty of Science
Ain Shams University

Dr. Nahla Samir Hassan
Assistant professor of Biochemistry
Faculty of Science
Ain Shams University

Dr. Nashwa Nagy EL-Khazragy
Consultant of Clinical/Molecular Pathology
Faculty of Medicine
Ain Shams University

Biochemistry department
Faculty of Science
Ain Shams University

2020

Ain Shams University
Faculty of science
Biochemistry Department

Approval sheet

Name of candidate / **Marwa Adel Abou- Elwafa**

Title of the thesis: **Evaluation of Some long non coding RNAs in Chronic Lymphocytic Leukemia**

This thesis has been approved for submission by:

Supervisors:

Prof. Dr. Magdy Mahmoud Mohamed

Professor of Biochemistry, Faculty of Science, Ain Shams University

Dr. Nahla Samir Hassan

Assistant professor of Biochemistry, Faculty of Science, Ain Shams University

Dr. Nashwa Nagy EL-Khazragy

Consultant of Clinical/Molecular Pathology, Faculty of Medicine, Ain Shams University

Examiners committee:

Prof. Dr. Zakaria Abdel Halim Al-Khayyat

Professor of Biochemistry at National Center for Research

Prof. Dr. Amany Abd El-Ghaffar Mahmoud

Professor of Biochemistry at Research Institute of Ophthalmology

Prof. Dr. Magdy Mahmoud Mohamed

Professor of Biochemistry, Faculty of Science, Ain Shams University

Head of Biochemistry Department

Prof. Dr. kholoud Salah El -Din

This thesis is dedicated to my Family especially my Mother for supporting me and pushing me forward all the time from A, B, C to the master degree.

ACKNOWLEDGMENT

First and foremost, I fell thankful to Allah, the most beneficial, the merciful and may peace and blessing is upon the Seal of the Prophets, Muhammad, his family and all his Companions.

I would like to express my deepest gratitude to **Prof. Dr. Magdy Mahmoud Mohamed,** professor of Biochemistry, Faculty of Science, Ain Shams University, the soul of this thesis, for his guidance and great help in all steps of his work and I think no words can express my deep sincere towards him.

My deepest appreciation to **Dr. Nahla Samir Hassan** Assistant Professor of Biochemistry, Faculty of Science, Ain Shams University, for her support and advice through this work, I think no words can express my deep sincere towards her.

I would like to express my great thanks to **Dr. Nashwa Nagy EL-Khazragy,** Consultant of Clinical/Molecular Pathology, Faculty of Medicine, Ain Shams University, for her great help, support and her patience with me.

Marwa Adel Abou- Elwafa

List of contents

Subject	Page No.
List of Abbreviations	i
List of Figures	v
List of Tables	viii
Abstract	
Introduction and Aim of the work	
Chapter I: Review of literature	
I-Chronic lymphocytic leukemia	5
1-Incidence of the disease	6
2- Pathogenesis of the disease	7
3- Etiology and Risk factors of CLL	11
Age and Gender	11
Racial Factor	11
Family history	11
Exposure to Chemicals	12
Monoclonal B-cell lymphocytosis	12
Cytogenetic and Molecular factors of CLL	13
4- Classification of the disease	14
French-American-British Classification of CLL	14
World Health Organization Classification of CLL	15
5- Clinical staging of the disease	18
Rai staging system	18
Binet staging system	19
6- Diagnosis of the disease	19
Morphological	19

Biochemical test 20
Immunophenotype.....20
Cytogenetic factor.....22
Molecular factor 22
7- Prognostic criteria of the disease.....23
8- Multi drug resistance in CLL 25
9- Detection of minimal residual disease.....26
10- Treatment of the disease.....26
Chemotherapy.....27
Radiotherapy.....28
Immunotherapy.....28
Chemo-immunotherapy.....28
New strategies of treatment.....29
II. NON CODING RNA.....30
1-Classification of Non coding RNA.....30
2-Structure and biosynthesis of Non coding RNA.....31
3- Function of Non coding RNA.....32
4-Long non coding RNA in disease.....33
5-Long non-coding RNA role in cancer.....36
Long Non coding RNA as a diagnostic marker for Cancer.....37
Long Non coding RNA as a prognostic marker for Cancer.....40
Non coding RNA as therapeutic Target for cancer.....41
Long non coding RNA interferon regulatory factor2-3…......44
Evolution.....44
Role in cancer.....44
Pathogenesis of lnc-IRF 2-3.....45
Application of lnc-IRF 2-3 in cancer 45
Long non coding RNA zinc finger factor 667.....45

Evolution.....46
Role in cancer.....46
Pathogenesis of lnc- ZNF667in cancer.....48
Application of lnc- ZNF667 in cancer.....49
6- Application of non-coding RNA.....50
III.Messenger RNA BAX and BCL2.....52
Chapter II: Subjects and methods.....
Chapter III: Results.....
Chapter IV: Discussion.....
Summary.....
Conclusion & Recommendation.....
References .....
Arabic Abstract.....
Arabic Summary.....

List of Abbreviations

Abbr.		Full-term
ABC	**:**	ATP-binding cassette
ACTB	**:**	β -Actin
ALL	**:**	Acute lymphocytic leukemia
AML	**:**	Acute myelogenous leukemia
AOC4P	**:**	Amine Oxidase Copper Containing 4 Pseudogene
ASOs	**:**	Antisense Oligonucleotides
BANCR	**:**	BRAF-Activated Non-Coding RNA
BAX	**:**	Bcl-2 Associated X
Bcl-2	**:**	B-cell lymphoma/leukemia-2
BCR	**:**	B-cell receptor
BET	**:**	Bromodomain And Extraterminal
BIRC3	**:**	Baculoviral IAP Repeat Containing 3
BL	**:**	Burkitt Lymphoma
BTK	**:**	Bruton's tyrosine kinase
β2-microglobulin	**:**	Beta-2-microglobulin
CBC	**:**	Complete blood cell count
CBR3-AS1	**:**	Carbonyl reductase 3
CC	**:**	Cervical cancer
CCAT1	**:**	Colon Cancer Associated Transcript 1
CCAT2	**:**	Colon Cancer-Associated Transcript-2
CD	**:**	Cluster of differentiation
circRNAs	**:**	Circular RNAs
CLL	**:**	Chronic lymphocytic leukemia
CLL/PL	**:**	B-chronic lymphocytic leukemia/ prolymphocytic
CML	**:**	Chronic myelogenous leukemia
CRC	**:**	Colorectal Cancer
DEPC-water	**:**	Diethyl Pyrocarbonate
DLBCL	**:**	Diffuse large B-cell lymphoma
ESCC	**:**	Esophageal Squamous Carcinoma
EZH2	**:**	Enhancer Of Zeste Homolog 2
FAB	**:**	French-American-British classification
FIGO	**:**	International Federation of Gynecology and

		Obstetrics
FISH	**:**	Fluorescent in situ hybridization
FL	**:**	Follicular lymphoma
FMASU	**:**	Faculty Of Medicine, Ain Shams University
GAS5	**:**	Growth Arrest-Specific 5
GATA3	**:**	GATA Binding Protein 3
GC	**:**	Gastric Cancer
HCC	**:**	Hepatocellular Carcinoma
HNSC	**:**	Head and neck squamous cell carcinoma
HOTAIR	**:**	HOX Antisense Intergenic RNA
HULC	**:**	Highly Upregulated Lncrna
IC-NOTCH	**:**	Intracellular domain- NOTCH
Ig	**:**	Immunoglobulin
IGHV	**:**	Immunoglobulin heavy chain variable
IPI	**:**	International Prognostic Index
IQR	**:**	Interquartile Range
JAK/STAT	**:**	Janus kinases/signal transducers
LDT	**:**	Lymphocyte doubling time
LINC00152	**:**	Long Intergenic Non-Protein Coding Rna 152
LINC00857	**:**	Long Intergenic Non-Protein Coding RNA 857
LincRNAs	**:**	Long Intergenic Non-Coding Rnas
Lnc-BACH1-1	**:**	Long non coding BTB and CNC homology 1
Lnc-IRF2-3	**:**	Long non coding interferon regulatory factor 2-3
LncRNA	**:**	Long non coding RNA
Lnc-ZNF667	**:**	Long non coding zinc finger factor 667
LPL	**:**	Lipoprotein lipase gene
LSCC	**:**	Laryngeal squamous cell carcinoma
MALAT1	**:**	Lung adenocarcinoma transcript 1
MBL	**:**	Monoclonal B lymphocytosis
MCL	**:**	Mantle cell lymphoma
MDR	**:**	Multi drug resistance
MIAT	**:**	Myocardial infarction associated transcript
micro-RNA	**:**	Micro ribonucleic acid
MM	**:**	Multiple myeloma
MORT	**:**	Mortal Obligate RNA Transcript
MRD	**:**	Minimal residual disease

mRNAs	**:**	Messenger RNAS
mTOR	**:**	Mammalian Target Of Rapamycin
NATs	**:**	Natural Antisense Transcripts
ncRNAs	**:**	Non-coding RNAs
NF-κB	**:**	Nuclear factor κB
NHL	**:**	Non-Hodgkin's lymphoma
NOTCH1	**:**	Notch homolog 1, translocation-associated
NPC	**:**	Nasopharyngeal Carcinoma
NS	**:**	Non-Significant
OS	**:**	Overall survival
OSCC	**:**	Oral squamous cell carcinoma
OSF	**:**	Oral sub-mucous fibrosis
P - value	**:**	Probability Value
PBS	**:**	Phosphate-Buffered Saline
PC	**:**	Plasma cell
PCa	**:**	Prostate Cancer
PCA3	**:**	Prostate Cancer Antigen 3 Gene
PCAT-1	**:**	Prostate Cancer Associated Transcript 1
PCAT-18	**:**	Prostate Cancer-Associated Noncoding RNA Transcript 18
PEG3	**:**	Paternally expressed gene 3
PFS	**:**	Progression-free survival
P-gp	**:**	P-glycoprotein
PLL	**:**	Prolymphocytic leukemia
qRT-PCR	**:**	Quantitative Real Time Polymerase Chain Reaction
ROC curve	**:**	Receiver Operating Characteristic Curve
SD	**:**	Standard Deviation
SF3B1	**:**	Splicing Factor 3b Subunit 1
SMZL	**:**	Splenic marginal zone lymphoma
snRNAs	**:**	Small Nuclear RNA
SPSS	**:**	Statistical Package For Social Science
TCGA	**:**	The Cancer Genome Atlas
TINCR	**:**	Terminal Differentiation-Induced Ncrna
TLR/IL-1R	**:**	Toll-like receptor/interleukin-1 receptor
TP53	**:**	Tumor protein p53
TUG1	**:**	Taurine Up Regulated Gene 1

UM-CLL	**:**	Un-mutated- CLL
WHO	**:**	World Health Organization
ZAP-70	**:**	Zeta-chain-associated protein kinase 70
ZNF667	**:**	Zinc Finger factor 667

List of Figures

Figure No.	Title	Page No.
Fig. (1)	Signaling pathways in CLL cells	8
Fig. (2)	Timeline of development of various treatment modalities in CLL.	27
Fig. (3)	Noncoding RNAs of the Human Transcriptome	31
Fig. (4)	Production of distinct classes of ncRNAs from mammalian genomes	32
Fig. (5)	A schematic representation of biological functions of non-coding RNAs showing their roles in alternative splicing, epigenetic regulation of gene expression, mRNA turnover, translational repression, activation and generation of siRNA	33
Fig. (6)	Some lncRNAs associated with cancers. The colour represents either up regulated (red) or down regulated (blue) compared to normal tissues	37
Fig. (7)	MiRNAs as cross-kingdom regulators	51
Fig. (8)	Total RNA Extraction Procedure using the"miRNeasy Serum/Plasma Kit" (Qiagen, Hilden, Germany).	61
Fig. (9)	Selective conversion of mature miRNAs into cDNA.	66
Fig. (10)	Step One (Applied BioSystems) PCR detection system.	69
Fig. (11)	Amplification plots of the threshold of expression of target genes by real time-qPCR.	72
Fig. (12)	The association of mean age in years among the studied groups	76
Fig. (13)	The association of gender among the studied groups	77
Fig. (14)	The distribution of B-CLL group according to Rai-staging	79
Fig. (15)	The distribution of B-CLL group according to Binet – staging	79